Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108
   PubMed Web of Science ®Google Scholar
• Sociedad Española de Oncología Médica (SEOM). Las cifras del cáncer en España 2014. Madrid: SEOM, 2014. www.seom.org/seomcms/images/stories/recursos/Las_cifras_del_cancer_2014.pdf. Accessed August 6, 2015
   Google Scholar
• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. globocan.iarc.fr/Default.aspx. AccessedAugust 6, 2015
   Google Scholar
• Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii1-9
   PubMed Web of Science ®Google Scholar
• Peeters M, Kafatos G, Taylor A, et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Eur J Cancer 2015;51:1704-13
   PubMed Web of Science ®Google Scholar
• Corral J, Borràs JM, Chiarello P, et al. Estimation of hospital costs of colorectal cancer in Catalonia. Gac Sanit 2015;29:437-44
   PubMed Web of Science ®Google Scholar
• Binefa G, Rodríguez-Moranta F, Teule A, et al. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol 2014;20:6786-808
   PubMed Web of Science ®Google Scholar
• Vera R, Alonso V, Gállego J, et al. Current controversies in the management of metastatic colorectal cancer. Cancer Chemother Pharmacol 2015;76:659-77
   PubMed Web of Science ®Google Scholar
• Navarro S, Musulén-Palet E, Cuatrecasas M, et al. Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. Rev Esp Patol 2015;48:14-24
   Google Scholar
• Vectibix® Summary of product characteristics. London: European Medicines Agency, 2015. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000741/WC500047710.pdf. Accessed August 6, 2015
   Google Scholar
• Avastin® Summary of product characteristics. London: European Medicines Agency, 2015. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf. Accessed August 6, 2015
   Google Scholar
• Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23:2479-516
   PubMed Web of Science ®Google Scholar
• Casado-Saenz E, Feliu J, Gomez-España MA, et al. SEOM clinical guidelines for the treatment of advanced colorectal cancer 2013. Clin Transl Oncol 2013;15:996-1003
   PubMed Web of Science ®Google Scholar
• Khattak MA, Martin H, Davidson A, et al. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin Colorectal Cancer 2015;14:81-90
   Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:1386-422
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32:2240-7
   PubMed Web of Science ®Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit 2010;24:154-70
   PubMed Web of Science ®Google Scholar
• Puig J, Oliva J, Trapero M, et al. Guía y recomendaciones para la realización y presentación de evaluaciones económicas y análisis de impacto presupuestario de medicamentos en el ámbito del CatSalut. Barcelona: Generalitat de Catalunya, Departament de Salut, Servei Català de la Salut, 2014. catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/farmaeconomica/caeip/documents/gaeip_publica_castellano_octubre2014_catsalut.pdf. Accessed June 22, 2015
   Google Scholar
• Lawrence D, Maschio M, Leahy KJ, et al. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer. J Med Econ 2013;16:1387-98
   PubMedGoogle Scholar
• Graham CN, Hechmati G, Hjelmgren J, et al. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 2014;50:2791-801
   PubMed Web of Science ®Google Scholar
• Fínek J, Skoupá J, Jandová P. Cost effectiveness analysis of panitumumab plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 for first-line treatment of patients with wildtype RAS metastatic colorectal cancer -  Czech Republic model adaptation. Klin Onkol 2015;28:265-72
   PubMedGoogle Scholar
• Vargas JJ, Alva ME. Cost-effectiveness analysis of panitumumab + FOLFOX in RAS-WT mCRC. GAMO 2015;14:250-8
   Google Scholar
• Kourlaba G, Boukovinas I, Saridaki Z, et al. Cost-effectiveness analysis of panitumumab + mFOLFOX over bevacizumab + mFOLFOX as a first-line treatment for metastatic colorectal cancer patients with Wild-Type RAS in Greece. Value Health 2014;17:A633
   Google Scholar
• Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment. An overview and guide. Pharmacoeconomics 2008;26:131-48
   PubMed Web of Science ®Google Scholar
• Culyer JA. The dictionary of health economics. 3rd edn. Cheltenham: Edward Elgar Publishing, 2014
   Google Scholar
• Cao Q, Buskens E, Feenstra T, et al. Continuous-time semi-Markov models in health economic decision making: an illustrative example in heart failure disease management. Med Decis Making 2016;36:59-71
   PubMed Web of Science ®Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force–3. Value Health 2012;15:812-20
   PubMed Web of Science ®Google Scholar
• Hettle R, Posnett J, Borrill J. Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer. J Med Econ 2015;18:516-24
   PubMed Web of Science ®Google Scholar
• Casciano R, Chulikavit M, Perrin A, et al. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. J Med Econ 2012;15(Suppl1):55-64
   PubMedGoogle Scholar
• Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-58
   PubMed Web of Science ®Google Scholar
• Karthaus M, Schwartzberg L, Rivera F, et al. Updated overall survival analysis of novel predictive KRAS/NRAS mutations beyond KRAS exon 2 in PEAK: A 1st-line phase 2 study of FOLFOX6 plus panitumumab or bevacizumab in metastatic colorectal cancer. Eur J Cancer 2013;49(Suppl 2):S1-S1028
   Google Scholar
• Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI {+/−} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:107-16
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• BOT Plus 2.0 [Internet]. Madrid: Consejo General del Colegio Oficial de Farmacéuticos, 2015. botplusweb.portalfarma.com. Accessed May 12, 2015
   Google Scholar
• Magaña M. Panitumumab en CCRm que exprese EGFR con KRAS no mutado. Grupo de Evaluación de Novedades, EStandarización e Investigación en Selección de medicamentos (GÉNESIS). Palma de Mallorca, Spain: Sociedad Española de Farmacia Hospitalaria, 2009. gruposdetrabajo.sefh.es/genesis/genesis/Documents/PANITUMUMAB_Hsll_0309.pdf. Accessed October 15, 2015
   Google Scholar
• Castillo MA, Ubago R, Navarro JA, et al. Anticuerpos monoclonales asociados a quimioterapia en el tratamiento de primera línea del cáncer colorrectal metastásico: eficacia, seguridad y eficiencia comparadas. Sevilla: Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, 2013. www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_6_2011_MAB_CaColorrectal.pdf. Accessed October 15, 2015
   Google Scholar
• Spanish Health Costs Database: eSalud [Internet]. Barcelona: Oblikue Consulting, S.L., 2007. www.oblikue.com/bddcostes/. Accessed February 1, 2015
   Google Scholar
• Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol Health States. Med Care 1997;35:1085-108
   Web of Science ®Google Scholar
• Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008;19:92-8
   PubMed Web of Science ®Google Scholar
• Corral MJ, Clopès A, Navarro M, et al. Impact on budget of new drugs for colorectal cancer treatment. Med Clin (Barc) 2007;129:134-6
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Del Llano J, et al. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002;16:334-43
   PubMedGoogle Scholar
• Rodríguez Barrios JM, Pérez Alcántara F, Crespo Palomo C, et al. The use of cost per life year gained as a measurement of cost-effectiveness in Spain: A systematic review of recent publications. Eur J Health Econ 2012;13:723-40
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ortendahl JD, Purdum AG, et al. Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States. Am J Clin Oncol 2015: published online September 22, 2015, http://journals.lww.com/amjclinicaloncology/Abstract/publishahead/Cost_Effectiveness_of_Cetuximab_as_First_line.99114.aspx doi: 10.1097/COC.0000000000000231
   PubMed Web of Science ®Google Scholar
• Graham CN, Hechmati G, Fakih MG, et al. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. J Med Econ 2015;18:619-28
   PubMed Web of Science ®Google Scholar
• Grávalos C, Fernández M, Gea S. Análisis de minimización de costes de panitumumab frente a cetuximab en combinación con quimioterapia en primera y segunda línea de tratamiento del cáncer colorrectal metastásico RAS no mutado en España. 3r Congreso de Oncología Médica y Farmacia Oncológica, Toledo (España); November 26–28, 2015
   Google Scholar
• Ewara EM, Zaric GS, Welch S, et al. Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer. Curr Oncol 2014;21:e541-50
   PubMed Web of Science ®Google Scholar
• Riesco MC, Berry SR, Ko YJ, et al. Cost-effective analysis of the use of EGFR inhibitors for wild-type KRAS unresectable metastatic colorectal cancer. J Clin Oncol 2013;31(Suppl):abstract 6552
   Google Scholar
• Lien K, Berry S, Ko YJ, et al. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective? Expert Rev Pharmacoecon Outcomes Res 2015;15:81-100
   PubMed Web of Science ®Google Scholar
• Huxley N, Crathorne L, Varley-Campbell J, et al. The clinical effectiveness and cost-effectiveness of cetuximab (review of TA176) and panitumumab (partial review of TA240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. PenTAG, University of Exeter Medical School (Report for NICE), 2015. www.nice.org.uk/guidance/GID-TAG470/documents/colorectal-cancer-metastatic-cetuximab-review-ta176-and-panitumumab-part-review-ta240-1st-line-id794-assessment-report2. Accessed October 20, 2015
   Google Scholar
• Pan-Canadian Oncology Drug Review. Initial Clinical Guidance Report Panitumumab (Vectibix) for Metastatic Colorectal Cancer. Toronto: Canadian Agency for Drugs and Technologies in Health, 2015. www.cadth.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_in_cgr.pdf. Accessed October 20, 2015
   Google Scholar
• Lange A, Prenzler A, Frank M, et al. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer 2014;50:40-9
   PubMed Web of Science ®Google Scholar
• Antoñanzas F, Juárez-Castelló CA, Rodríguez-Ibeas R. Some economics on personalized and predictive medicine. Eur J Health Econ 2015;16:985-94
   PubMed Web of Science ®Google Scholar
• Sorbye H, Cvancarova M, Qvortrup C, et al. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol 2013;24:2354-60
   PubMed Web of Science ®Google Scholar
• Marsh K, Phillips CJ, Fordham R, et al. Estimating cost-effectiveness in public health: a summary of modelling and valuation methods. Health Econ Rev 2012;2:17
   PubMedGoogle Scholar
• Shiroiwa T, Fukuda T, Shimozuma K, et al. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan. Pharmacoeconomics 2009;27:597-608
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Cremolini C, Petrelli F, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2015;96:156-66
   PubMed Web of Science ®Google Scholar